New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:17 EDTBTI, DEO, GSK, ITYBY, NVS, SHPGCredit Suisse to hold a conference
Stockholm Consumer & Healthcare IR Day to be held in Stockholm, Sweden on May 14.
News For BTI;DEO;GSK;ITYBY;NVS;SHPG From The Last 14 Days
Check below for free stories on BTI;DEO;GSK;ITYBY;NVS;SHPG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 17, 2014
14:57 EDTGSKProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
07:43 EDTSHPGBofA/Merrill to hold a conference
Subscribe for More Information
07:39 EDTGSKMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
September 16, 2014
11:51 EDTSHPGOECD looks to close tax loopholes with new proposals
Subscribe for More Information
07:33 EDTGSKMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:31 EDTGSK, NVSEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
16:10 EDTGSKFive Prime announces option exercise by GlaxoSmithKline to obtain license
Subscribe for More Information
10:55 EDTSHPGRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
08:01 EDTSHPGShire announces FDA acceptance for filing of sNDA for Vyvanse
Subscribe for More Information
07:27 EDTNVS, GSKIBC Life Sciences to hold a conference
Subscribe for More Information
07:21 EDTNVSHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 12, 2014
05:18 EDTNVSNovartis announces new data confirms high efficacy of Gilenya in achieving NEDA
Novartis announced new analyses presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA, which confirmed the high efficacy of Gilenya in achieving 'no evidence of disease activity', or NEDA, in people with relapsing-remitting multiple sclerosis, or RRMS, across four key disease measures - relapses, MRI lesions, brain shrinkage and disability progression. Specifically, patients taking Gilenya had a more than four-times greater likelihood of achieving NEDA across these four key measures. NEDA is currently defined as having no relapses, MRI lesions and disability progression. These new analyses from the phase III FREEDOMS and FREEDOMS II trials reinforce the value of including brain shrinkage to the definition of NEDA. The inclusion of brain shrinkage into the NEDA definition would allow physicians to obtain a more complete assessment of a patient's disease, including the underlying damage in MS.
September 10, 2014
09:58 EDTGSKGlaxoSmithKline has a conference call hosted by JPMorgan
Subscribe for More Information
08:37 EDTSHPGMedgenics appoints Scott Applebaum as Chief Legal Officer
Subscribe for More Information
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
05:17 EDTNVSNovartis Gilenya data confirms reducing brain shrinkage matter for MS patients
Subscribe for More Information
September 9, 2014
10:10 EDTDEOOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
07:55 EDTNVSOphthotech earlier than expected Novartis payment positive, says Oppenheimer
After Ophthotech (OPHT) received a $50M Phase 3 enrollment payment from Novartis (NVS) earlier than expected, Oppenheimer thinks the payment highlights an underappreciated stock driver for Opthotech, and demonstrates that recent suggestions of Phase 3 enrollment timelines possibly slipping are unwarranted. The firm believes the company is executing well on the Fovista Phase 3 program and keeps an Outperform rating on the stock.
07:43 EDTDEODiageo upgraded to Buy from Neutral at BTIG
06:25 EDTGSKDocuments show DOJ probed GSK China unit in 2012, Reuters says
Internal documents revealed that a U.S. anti-bribery investigation into GlaxoSmithKline (GSK) touched on the firm's Chinese consumer healthcare division two years ago, which infers that the company's compliance issues in the country could be broader than initially discovered, according to Reuters, citing the documents. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use